Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Xu-Fen Zeng, Krista A Varady, Xiang-Dong Wang, Giovanni Targher, Christopher D Byrne, Reema Tayyem, Giovanni Latella, Ina Bergheim, Rodrigo Valenzuela, Jacob George, Carolyn Newberry, Ju-Sheng Zheng, Elena S George, C Wendy Spearman, Meropi D Kontogianni, Danijela Ristic-Medic, Wilza Arantes Ferreira Peres, Gamze Yurtdaş Depboylu, Wanshui Yang, Xu Chen, Fredrik Rosqvist, Christos S Mantzoros, Luca Valenti, Hannele Yki-Järvinen, Antonella Mosca, Silvia Sookoian, Anoop Misra, Yusuf Yilmaz, Won Kim, Yasser Fouad, Giada Sebastiani, Vincent Wai-Sun Wong, Fredrik Åberg, Yu Jun Wong, Pianhong Zhang, Francisco-Javier Bermúdez-Silva, Yan Ni, Monica Lupsor-Platon, Wah Kheong Chan, Nahum Méndez-Sánchez, Robert J de Knegt, Shahinul Alam, Sombat Treeprasertsuk, Li Wang, Mulong Du, Tiejun Zhang, Ming-Lung Yu, Huijie Zhang, Xingshun Qi, Xin Liu, Kanokwan Pinyopornpanish, Yu-Chen Fan, Niu Kaijun, Josep C Jimenez-Chillaron, Ming-Hua Zheng
Metabolic dysfunction-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD), has become the leading cause of chronic liver disease worldwide. Optimal dietary intervention strategies for MAFLD are not standardized. This study aimed to achieve consensus on prevention of MAFLD through dietary modification. A multidisciplinary panel of 55 international experts, including specialists in hepatology, gastroenterology, dietetics, endocrinology and other medical specialties from six continents collaborated in a Delphi-based consensus development process...
September 11, 2024: Metabolism: Clinical and Experimental
#2
JOURNAL ARTICLE
Huangda Guo, Siyue Wang, Hexiang Peng, Weiwei Wang, Tianjiao Hou, Yixin Li, Hanyu Zhang, Jin Jiang, Bohao Ma, Yilei Qin, Mengying Wang, Liming Li, Jie Huang, Tao Wu
BACKGROUND: Recently, the American Heart Association introduced Life's Essential 8 (LE8) as a new cardiovascular health (CVH) metric, and studies have reported associations between LE8 and CVH outcomes. However, there is limited understanding of LE8's impact on the risk of transitions between different stages of CVH. The current study investigated whether adhering to LE8 during a healthy stage could mitigate the progression from hypertension (HT) to cardiovascular diseases (CVDs), and consequent death...
September 10, 2024: Metabolism: Clinical and Experimental
#3
JOURNAL ARTICLE
Blanka Holendová, Barbora Šalovská, Štěpánka Benáková, Lydie Plecitá-Hlavatá
OBJECTIVE: Redox signaling mediated by reversible oxidative cysteine thiol modifications is crucial for driving cellular adaptation to dynamic environmental changes, maintaining homeostasis, and ensuring proper function. This is particularly critical in pancreatic β-cells, which are highly metabolically active and play a specialized role in whole organism glucose homeostasis. Glucose stimulation in β-cells triggers signals leading to insulin secretion, including changes in ATP/ADP ratio and intracellular calcium levels...
September 9, 2024: Metabolism: Clinical and Experimental
#4
REVIEW
Heike Münzberg, Steven B Heymsfield, Hans-Rudolf Berthoud, Christopher D Morrison
The cloning of leptin 30 years ago in 1994 was an important milestone in obesity research. Prior to the discovery of leptin, obesity was stigmatized as a condition caused by lack of character and self-control. Mutations in either leptin or its receptor were the first single gene mutations found to cause severe obesity, and it is now recognized that obesity is caused mostly by a dysregulation of central neuronal circuits. Since the discovery of the leptin-deficient obese mouse (ob/ob) the cloning of leptin (ob aka lep) and leptin receptor (db aka lepr) genes, we have learned much about leptin and its action in the central nervous system...
September 6, 2024: Metabolism: Clinical and Experimental
#5
REVIEW
Qianquan Ma, Haoyu Li, Zhihao Song, Zhili Deng, Wei Huang, Qing Liu
Metabolism of Branched-chain amino acids (BCAAs) is essential for the nutrient necessities in mammals. Catalytic enzymes serve to direct the whole-body BCAAs oxidation which involve in the development of various metabolic disorders. The reprogrammed metabolic elements are also responsible for malignant oncogenic processes, and favor the formation of distinctive immunosuppressive microenvironment surrounding different cancers. The impotent immune surveillance related to BCAAs dysfunction is a novel topic to investigate...
August 31, 2024: Metabolism: Clinical and Experimental
#6
REVIEW
Tian Lan, Frank Tacke
The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) continues to rise, making it the leading etiology of chronic liver diseases and a prime cause of liver-related mortality. MASLD can progress into steatohepatitis (termed MASH), fibrosis, cirrhosis, and ultimately cancer. MASLD is associated with increased risks of hepatocellular carcinoma (HCC) and also extrahepatic malignancies, which can develop in both cirrhotic and non-cirrhotic patients, emphasizing the importance of identifying patients with MASLD at risk of developing MASLD-associated malignancies...
August 29, 2024: Metabolism: Clinical and Experimental
#7
REVIEW
Markos Kalligeros, Linda Henry, Zobair M Younossi
Metabolic-dysfunction associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is a growing global health concern with significant implications for oncogenesis. This review synthesizes current evidence on the association between MASLD and cancer risk, highlighting its role as a risk factor for both intrahepatic and extrahepatic malignancies. MASLD is increasingly recognized as a major cause of hepatocellular carcinoma (HCC), with its incidence rising in parallel with the prevalence of metabolic dysfunction...
August 23, 2024: Metabolism: Clinical and Experimental
#8
REVIEW
Alessandro Mantovani, Amedeo Lonardo, Norbert Stefan, Giovanni Targher
Metabolic dysfunction-associated steatotic liver disease (MASLD) poses a significant and ever-increasing health and economic burden worldwide. Substantial epidemiological evidence shows that MASLD is a multisystem disease that is associated not only with liver-related complications but is also associated with an increased risk of developing cardiometabolic comorbidities and extrahepatic cancers (principally gastrointestinal [GI] cancers). GI cancers account for a quarter of the global cancer incidence and a third of cancer-related deaths...
August 23, 2024: Metabolism: Clinical and Experimental
#9
JOURNAL ARTICLE
Ji Hee Lim, Yaeni Kim, Min Young Kim, Eun Nim Kim, Tae Woo Kim, Bum Soon Choi, Wan-Uk Kim, Hye Won Kim, Ji Yong Park, Cheol Whee Park
Obesity often leads to inadequate angiogenesis in expanding adipose tissue, resulting in inflammation and insulin resistance. We explored the role of placental growth factor (PlGF) in metabolic syndrome (MS) using mice models of type 2 diabetes, high-fat diet, or aging. Reduced serum PlGF levels were associated with decreased insulin sensitivity and development of MS features. PlGF was localized within endothelial cells and pericytes of adipose tissue. In vitro, low PlGF levels in hypoxic conditions worsened oxidative stress, apoptosis, and reduced autophagy...
August 20, 2024: Metabolism: Clinical and Experimental
#10
JOURNAL ARTICLE
Ramesh C Mishra, Darrell D Belke, Latika Singh, Heike Wulff, Andrew P Braun
OBJECTIVE: This study tested the hypothesis that administration of the KCa channel activator SKA-31 restores endothelium-dependent vasodilation in vivo in Type 2 Diabetic (T2D) rats. BACKGROUND: Acute treatment of isolated resistance arteries from T2D rats and humans with SKA-31 significantly improved endothelium-dependent vasodilation. However, it is unknown whether these in situ actions translate to intact vascular beds in vivo. METHODS: Male Sprague Dawley (SD) and T2D Goto-Kakizaki (GK) rats (26-32 weeks of age) were injected intraperitoneally with either drug vehicle or 10 mg/kg SKA-31...
August 18, 2024: Metabolism: Clinical and Experimental
#11
JOURNAL ARTICLE
Huai Zhang, Xiao-Dong Zhou, Michael D Shapiro, Gregory Y H Lip, Herbert Tilg, Luca Valenti, Virend K Somers, Christopher D Byrne, Giovanni Targher, Wah Yang, Octavio Viveiros, Christopher Kenneth Opio, Christos S Mantzoros, John D Ryan, Kenneth Yuh Yen Kok, Nozim Adxamovich Jumaev, Nilanka Perera, Andrew Gerard Robertson, Adam Abu-Abeid, Anoop Misra, Yu Jun Wong, Elena Ruiz-Úcar, Oral Ospanov, Mehmet Celal Kızılkaya, Fei Luo, Nahum Méndez-Sánchez, Mauricio Zuluaga, Amedeo Lonardo, Hazem Al Momani, Carlos Jesus Toro-Huamanchumo, Leon Adams, Said A Al-Busafi, Ala I Sharara, Wah-Kheong Chan, Syed Imran Abbas, Silvia Sookoian, Sombat Treeprasertsuk, Ponsiano Ocama, Khalid Alswat, Alice Pik-Shan Kong, Karim Ataya, Michelle Ching Lim-Loo, Rodolfo J Oviedo, Olivia Szepietowski, Yasser Fouad, Huijie Zhang, Tamer N Abdelbaki, Christos S Katsouras, Arun Prasad, Omar Thaher, Arshad Ali, Gabriel Alejandro Molina, Ki-Chul Sung, Qin-Fen Chen, Cosmas Rinaldi Adithya Lesmana, Ming-Hua Zheng
BACKGROUND: Common metabolic diseases, such as type 2 diabetes mellitus (T2DM), hypertension, obesity, hypercholesterolemia, and metabolic dysfunction-associated steatotic liver disease (MASLD), have become a global health burden in the last three decades. The Global Burden of Disease, Injuries, and Risk Factors Study (GBD) data enables the first insights into the trends and burdens of these metabolic diseases from 1990 to 2021, highlighting regional, temporal and differences by sex. METHODS: Global estimates of disability-adjusted life years (DALYs) and deaths from GBD 2021 were analyzed for common metabolic diseases (T2DM, hypertension, obesity, hypercholesterolemia, and MASLD)...
August 14, 2024: Metabolism: Clinical and Experimental
#12
REVIEW
Charalampos G Pontikoglou, Theodosios D Filippatos, Angelos Matheakakis, Helen A Papadaki
The rising prevalence of obesity-related illnesses, such as metabolic steatotic liver disease (MASLD), represents a significant global public health concern. This disease affects approximately 30 % of the adult population and is the result of metabolic abnormalities rather than alcohol consumption. Additionally, MASLD is associated with an increased risk of cardiovascular disease (CVD), chronic liver disease, and a variety of cancers, particularly gastrointestinal cancers. Clonal hematopoiesis (CH) is a biological state characterized by the expansion of a population of blood cells derived from a single mutated hematopoietic stem cell...
August 12, 2024: Metabolism: Clinical and Experimental
#13
EDITORIAL
Angeliki M Angelidi, Despina Sanoudou, Michael A Hill, Christos S Mantzoros
No abstract text is available yet for this article.
August 12, 2024: Metabolism: Clinical and Experimental
#14
REVIEW
Tiantian Wang, Dong Zhou, Zhen Hong
Sarcopenia is a geriatric syndrome characterized by a functional decline in muscle. The prevalence of sarcopenia increases with natural aging, becoming a serious health problem among elderly individuals. Therefore, understanding the pathology of sarcopenia is critical for inhibiting age-related alterations and promoting health and longevity in elderly individuals. The development of sarcopenia may be influenced by interactions between visceral and subcutaneous adipose tissue and skeletal muscle, particularly under conditions of chronic low-grade inflammation and metabolic dysfunction...
August 10, 2024: Metabolism: Clinical and Experimental
#15
JOURNAL ARTICLE
Jihao Wu, Xiong Chen, Ruijun Li, Qiying Lu, Yucheng Ba, Jiayun Fang, Yilin Liu, Ruijie Li, Yixuan Liu, Yiling Wang, Jinsi Chen, Yanbing Li, Yinong Huang
BACKGROUND: Sarcopenia, characterized by progressive muscle mass and function loss, particularly affects the elderly, and leads to severe consequences such as falls and mortality. Despite its prevalence, targeted pharmacotherapies for sarcopenia are lacking. Utilizing large-sample genome-wide association studies (GWAS) data is crucial for cost-effective drug discovery. METHODS: Herein, we conducted four studies to understand the putative causal effects of genetic components on muscle mass and function...
August 6, 2024: Metabolism: Clinical and Experimental
#16
JOURNAL ARTICLE
Shan Zhou, Xian Ling, Ye Liang, Qijian Feng, Chao Xie, Jiemei Li, Qiyan Chen, Jinhua Miao, Mengyao Zhang, Zhiru Li, Weiwei Shen, Xiaolong Li, Qinyu Wu, Xiaoxu Wang, Fan Fan Hou, Youhua Liu, Yaozhong Kong, Lili Zhou
AIMS: Renal fibrosis is a common feature in various chronic kidney diseases (CKD). Tubular cell damage is a main characterization which results from dysregulated fatty acid oxidation (FAO) and lipid accumulation. Cannabinoid Receptor 2 (CB2) contributes to renal fibrosis, however, its role in FAO dysregulation in tubular cells is not clarified. In this study, we found CB2 plays a detrimental role in lipid metabolism in tubular cells. METHODS: CB2 knockout mice were adopted to be induced a folic acid-induced nephropathy (FAN) model...
August 1, 2024: Metabolism: Clinical and Experimental
#17
JOURNAL ARTICLE
Konstantinos Stefanakis, Martina Samiotaki, Vassiliki Papaevangelou, Laura Valenzuela-Vallejo, Nick Giannoukakis, Christos S Mantzoros
BACKGROUND: Leptin is known for its metabolic, immunomodulatory and neuroendocrine properties, but the full spectrum of molecules downstream of leptin and relevant underlying mechanisms remain to be fully clarified. Our objective was to identify proteins and pathways influenced by leptin through untargeted proteomics in two clinical trials involving leptin administration in lean individuals. METHODS: We performed untargeted liquid chromatography-tandem mass spectrometry serum proteomics across two studies a) short-term randomized controlled crossover study of lean male and female humans undergoing a 72-h fast with concurrent administration of either placebo or high-dose leptin; b) long-term (36-week) randomized controlled trial of leptin replacement therapy in human females with acquired relative energy deficiency and hypoleptinemia...
August 1, 2024: Metabolism: Clinical and Experimental
#18
JOURNAL ARTICLE
Jeong Suk Kang, Nam-Jun Cho, Seong Woo Lee, Jeong Geon Lee, Ji-Hye Lee, Jawoon Yi, Min Sun Choi, Samel Park, Hyo-Wook Gil, Joon Cheol Oh, Seung Seob Son, Mi Ju Park, Jong-Seok Moon, Donghyeong Lee, So-Young Kim, Seung-Hoon Yang, Sang Soo Kim, Eun Soo Lee, Choon Hee Chung, Jihwan Parkf, Eun Young Lee
BACKGROUND: Receptor-interacting protein kinase (RIPK)3 is an essential molecule for necroptosis and its role in kidney fibrosis has been investigated using various kidney injury models. However, the relevance and the underlying mechanisms of RIPK3 to podocyte injury in albuminuric diabetic kidney disease (DKD) remain unclear. Here, we investigated the role of RIPK3 in glomerular injury of DKD. METHODS: We analyzed RIPK3 expression levels in the kidneys of patients with biopsy-proven DKD and animal models of DKD...
July 30, 2024: Metabolism: Clinical and Experimental
#19
JOURNAL ARTICLE
Dominic Arold, Stefan R Bornstein, Nikolaos Perakakis, Stefan Ehrlich, Fabio Bernardoni
BACKGROUND: Steatotic liver disease (SLD) is characterized by excessive accumulation of lipids in the liver. It is associated with elevated risk of hepatic and cardiometabolic diseases, as well as mental disorders such as depression. Previous studies revealed global gray matter reduction in SLD. To investigate a possible shared neurobiology with depression, we examined liver-fat-related regional gray matter alterations in SLD and its most significant clinical subgroup metabolic dysfunction-associated steatotic liver disease (MASLD)...
July 30, 2024: Metabolism: Clinical and Experimental
#20
JOURNAL ARTICLE
Increased adrenal steroidogenesis and suppressed corticosteroid responsiveness in critical COVID-19.
Tian-Zi Wen, Tian-Ran Li, Xin-Yu Chen, He-Yuan Chen, Shuai Wang, Wen-Juan Fu, Shi-Qi Xiao, Jie Luo, Rui Tang, Jia-Le Ji, Jia-Feng Huang, Zhi-Cheng He, Tao Luo, Hong-Liang Zhao, Cong Chen, Jing-Ya Miao, Qin Niu, Yan Wang, Xiu-Wu Bian, Xiao-Hong Yao
BACKGROUND: The effect of coronavirus disease 2019 (COVID-19) on adrenal endocrine metabolism in critically ill patients remains unclear. This study aimed to investigate the alterations in adrenal steroidogenic activity, elucidate underlying mechanisms, provide in situ histopathological evidence, and examine the clinical implications. METHODS: The comparative analyses of the adrenal cortices from 24 patients with fatal COVID-19 and 20 matched controls was performed, excluding patients previously treated with glucocorticoids...
July 23, 2024: Metabolism: Clinical and Experimental
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
